title: Osteoprotegerin is not associated with angiographic coronary calcification.
abstract: Coronary artery calcification may play a significant role in the pathophysiology of plaque progression and healing. We hypothesized that osteoprotegerin, an inhibitor of osteoclastogenesis, may participate in the calcification of coronary plaques or the response to injury after coronary stenting. A prospective registry was performed in 2004. Blood samples from 100 patients undergoing percutaneous coronary intervention (PCI) were obtained before PCI and 24 h after PCI. The concentrations of osteoprotegerin (OPG), C-reactive protein, interleukin-6, and soluble CD40 ligand (sCD40L) were determined by ELISA. Quantitative coronary angiography was performed to define the presence of culprit lesion calcification (CLC). Comparisons among markers of inflammation and tertiles of OPG were stratified with respect to CLC. Patients with CLC (n = 28) compared with no CLC (n = 71) were older (P < 0.01), had lower creatinine clearance (P < 0.01), lower hemoglobin (P = 0.02), and were less likely to smoke (P = 0.04). Patients without CLC were over twice as likely to present with a marker-positive acute coronary syndrome. CLC was associated with less pre-PCI platelet-mediated inflammation as measured by sCD40L (4.65 vs. 7.15 pg/ml, P = 0.05), but not with lower levels of OPG. Inflammatory cytokines increased significantly after PCI for patients with and without CLC. For patients in the highest tertile of OPG at baseline, there was a reduction in OPG after PCI. Systemic osteoprotegerin levels are not associated with angiographic calcification of culprit plaques. For patients with elevated levels of OPG prior to PCI, there is a significant reduction after PCI consistent with a counterregulatory role for OPG.
  
  
  CONCLUSIONS
  Both calcified and non-calcified culprit plaques exhibited a similar inflammatory response to stent-mediated injury. After PCI, osteoprotegerin decreased while proinflammatory cytokines increased, which may be consistent with a counterregulatory role for osteoprotegerin.
authors.affiliation: Division of Cardiology, University of Vermont College of Medicine, Burlington, VT 05401, USA. prospero.gogo@vtmednet.org
authors.forename: Prospero B
authors.initials: PB
authors.lastname: Gogo
authors.forename: David J
authors.initials: DJ
authors.lastname: Schneider
authors.forename: Edward F
authors.initials: EF
authors.lastname: Terrien
authors.forename: Burton E
authors.initials: BE
authors.lastname: Sobel
authors.forename: Harold L
authors.initials: HL
authors.lastname: Dauerman
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D002114:Calcinosis / Q000276:immunology / Q000503:physiopathology*; D009202:Cardiomyopathies / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology*; D017023:Coronary Angiography; D003331:Coronary Vessels / Q000293:injuries / Q000473:pathology*; D016207:Cytokines / Q000097:blood; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood*; D008297:Male; D008875:Middle Aged; D053244:Osteoprotegerin / Q000097:blood / Q000378:metabolism*; D011446:Prospective Studies; D015607:Stents / Q000009:adverse effects
chemical_list: D016207:Cytokines; D053244:Osteoprotegerin